Our team works at the interface of immunology, tumor biology and glycobiology, using in vitro and in vivo approaches, to understand how the molecular interactions between endogenous lectins and their ligands can mediate cellular processes relevant to immune response and angiogenesis. For more than 20 years, we have investigated the role of glycan-binding proteins in mediating cellular processes central to immune regulation and human diseases. Our goal is to contribute with new findings that bridge the gap between fundamental glycoscience and immunobiology and develop novel therapeutic targets in inflammation, autoimmunity, and cancer. Our studies, summarized in more than 300 publications in world-leading journals, allowed the identification of a novel paradigm based on galectin-glycan interactions in immunological homeostasis and the design of novel therapeutic approaches.